Advanced search
Publication Cover
Clinical Interventions in Aging Volume 4, 2009 - Issue
Submit an article Journal homepage
74
Views
15
CrossRef citations to date
0
Altmetric
Original Research

Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe?

Dimitrios A Karagiannis1 Ophthalmiatrio Eye Hospital of Athens, Athens, GreeceCorrespondence[email protected]
,
Ioannis D Ladas2 First Department of Ophthalmology, Medical School of Athens University, General Hospital of Athens, Athens, Greece
,
Efstratios Parikakis1 Ophthalmiatrio Eye Hospital of Athens, Athens, Greece
,
Ilias Georgalas2 First Department of Ophthalmology, Medical School of Athens University, General Hospital of Athens, Athens, Greece
,
Athanasios Kotsolis2 First Department of Ophthalmology, Medical School of Athens University, General Hospital of Athens, Athens, Greece
,
Giorgos Amariotakis1 Ophthalmiatrio Eye Hospital of Athens, Athens, Greece
,
Vasileios Soumplis1 Ophthalmiatrio Eye Hospital of Athens, Athens, Greece
&
Panagiotis Mitropoulos1 Ophthalmiatrio Eye Hospital of Athens, Athens, Greece
 show all
Pages 457-461 | Published online: 26 Nov 2009

Citations (15)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Daniele Tognetto, Eirini Skiadaresi, Paolo Cecchini & Giuseppe Ravalico. (2011) Subretinal recombinant tissue plasminogen activator and pneumatic displacement for the management of subretinal hemorrhage occurring after anti-VEGF injections for wet AMD. Clinical Ophthalmology 5, pages 459-463.
Read now

Articles from other publishers (14)

Kimberly Spooner, Thomas Hong, Rashmi Nair, Nicholas Chian Chiang Chow, Geoffrey K. Broadhead, Wijeyanthy Wijeyakumar & Andrew A. Chang. (2019) Long‐term outcomes of switching to aflibercept for treatment‐resistant neovascular age‐related macular degeneration. Acta Ophthalmologica 97:5.
Crossref
Mehrzad Zargarzadeh, Hamid Reza MadaahHosseini, Hamid Delavari, Rasoul Irajirad & Ermia Aghaie. (2018) Synthesis of magnetite (Fe 3 O 4 )–Avastin nanocomposite as a potential drug for AMD treatment . Micro & Nano Letters 13:8, pages 1141-1145.
Crossref
Delphine LamOudy SemounRocio Blanco-Garavito, Camille Jung, Diem T. NguyenEric H. SouiedGerard Mimoun. (2018) WRINKLED VASCULARIZED RETINAL PIGMENT EPITHELIUM DETACHMENT PROGNOSIS AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY. Retina 38:6, pages 1100-1109.
Crossref
Michele ReibaldiAlfredo PulvirentiTeresio AvitabileVincenza BonfiglioAndrea RussoCesare MariottiClaudio Bucolo, Rodolfo MastropasquaGuglielmo ParisiAntonio Longo. (2018) POOLED ESTIMATES OF INCIDENCE OF ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION OF ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS WITH AND WITHOUT TOPICAL ANTIBIOTIC PROPHYLAXIS. Retina 38:1, pages 01-11.
Crossref
Karen Jhi Wen Chia, Dinesh Visva Gunasekeran & Augustinus Laude. (2017) The Impact of Switching Anti-Vascular Endothelial Growth Factor Therapy in the Management of Exudative Age-Related Macular Degeneration. Ophthalmic Surgery, Lasers and Imaging Retina 48:10, pages 859-869.
Crossref
Dinu Stanescu-Segall, Florian Balta & Timothy L. Jackson. (2016) Submacular hemorrhage in neovascular age-related macular degeneration: A synthesis of the literature. Survey of Ophthalmology 61:1, pages 18-32.
Crossref
Elad Moisseiev, Gabriel Katz, Joseph Moisseiev, Anat Loewenstein, Michaella Goldstein, Yosef Lomnicky, Yitzhak Abend, Giora Treister, Dafna Goldenberg & Hana Levkovitch-Verbin. (2015) SWITCHING TREATMENT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION FROM BEVACIZUMAB TO RANIBIZUMAB. Retina 35:7, pages 1323-1330.
Crossref
Cem KüçükerdönmezMD, FEBOMD, FEBO, Faik Gelisken, Efdal Yoeruek, Karl Ulrich Bartz-Schmidt & Martin Alexander Leitritz. (2014) Switching Intravitreal anti-VEGF Treatment in Neovascular Age-Related Macular Degeneration. European Journal of Ophthalmology 25:1, pages 51-56.
Crossref
Geoffrey K. Broadhead, Thomas Hong & Andrew A. Chang. (2014) Treating the untreatable patient: current options for the management of treatment-resistant neovascular age-related macular degeneration. Acta Ophthalmologica 92:8, pages 713-723.
Crossref
C Ehlken, S Jungmann, D Böhringer, H T Agostini, B Junker & A Pielen. (2014) Switch of anti-VEGF agents is an option for nonresponders in the treatment of AMD. Eye 28:5, pages 538-545.
Crossref
João Pinheiro-Costa, Paulo Freitas-da-Costa, Manuel S. Falcão, Elisete M. Brandão, Fernando Falcão-Reis & Ângela M. Carneiro. (2014) Switch from Intravitreal Ranibizumab to Bevacizumab for the Treatment of Neovascular Age-Related Macular Degeneration: Clinical Comparison. Ophthalmologica 232:3, pages 149-155.
Crossref
Murat Aslankurt, Lokman Aslan, Adnan Aksoy, Burak Erden & Osman Çekiç. (2013) The Results of Switching between 2 Anti-VEGF Drugs, Bevacizumab and Ranibizumab, in the Treatment of Neovascular Age-related Macular Degeneration. European Journal of Ophthalmology 23:4, pages 553-557.
Crossref
Efstathios T. Detorakis, George Agorogiannis, Eleni E. Drakonaki, Miltiadis K. Tsilimbaris & Ioannis G. Pallikaris. (2012) Successful Management of Choroidal Metastasis With Intravitreal Ranibizumab Injections. Ophthalmic Surgery, Lasers and Imaging Retina 43:6.
Crossref
Jerrod S. Kent, Yiannis Iordanous, Alex Mao, Anne-Marie Powell, Shefalee Shukla Kent & Tom G. Sheidow. (2012) Comparison of outcomes after switching treatment from intravitreal bevacizumab to ranibizumab in neovascular age-related macular degeneration. Canadian Journal of Ophthalmology 47:2, pages 159-164.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.